| http://www.w3.org/ns/prov#value | - Alirocumab is the first nonstatin that appears to reduce additional cardiovascular events on top of statin therapy, and this is very encouraging since previous trials of various lipid-lowering and other drugs have failed to find this, said principal investigator Jennifer Robinson, MD, from the University of Iowa, Iowa City, IA, in the USA. Given the data available, alirocumab should prove a usef
|
